ReviewFrontiers in endocrinology2022

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.

Baptist GallwitzPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.